Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
Inhibrx Biosciences (INBX) reported positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs 26.5% for pembrolizumab alone, with 9.6-month median PFS. HPV+ patients saw even stronger results. The company plans to expand the trial and explore further applications. INBRX-106 is a hexavalent OX40 agonist.
How this was made
The 30-second read
Why it matters
The trial’s positive results could accelerate development timelines, attract partnership interest, and increase valuation. However, further data in HPV‑negative cohorts and Phase 3 outcomes are needed to sustain momentum.
Market read
First‑time disclosure of robust Phase 2 efficacy for a novel OX40 agonist, likely to move INBX stock and influence the immuno‑oncology sector.
What to watch
Safety profile appears manageable, but long‑term toxicity and regulatory hurdles for accelerated approval are uncertain.
Background
Inhibrx Biosciences (NASDAQ: INBX) is a clinical‑stage biotech focusing on multivalent antibody platforms. The HexAgon study evaluates INBRX‑106 with pembrolizumab in first‑line HNSCC.
Ticker impact
Inhibrx announced Phase 2 results for INBRX-106 showing 48.3% cORR and median PFS of 9.6 months versus pembrolizumab alone.
upward pressure in the short term, potential 10‑15% rally if market digests data positively.
First disclosure of statistically significant efficacy in a head‑and‑neck cancer trial; investors typically reward such breakthroughs.
Market effects
Strengthens the OX40 agonist and broader immuno‑oncology pipeline, may benefit peers developing costimulatory antibodies.
US biotech sector could see modest uplift; European sites participating in trial may see localized interest.
Adds to global oncology pipeline momentum, could influence biotech ETFs and cancer‑therapy focused funds.
Counterpoint
Phase 2 data may be over‑hyped; efficacy in HPV‑negative patients remains unclear and larger Phase 3 could miss expectations.
Key entities
- ExecutiveMark Lappe
Co‑founder and CEO of Inhibrx, quoted on trial results.
- DrugPembrolizumab
PD‑1 inhibitor used as monotherapy control in the study.
